Avadel Pharmaceuticals plc
Biotechnology ResearchView the employees at
Avadel Pharmaceuticals plc-
Brian Werner Vice President, Financial Operations at Avadel Pharmaceuticals plc
-
Rising Star
Bill Wu Territory Sales Manager- Rare Disease-
Kansas City, Missouri, United States
-
Top 5%
Derek Joyce, CPA Senior Financial Reporting Analyst at Avadel Pharmaceuticals-
St Louis, Missouri, United States
-
Top 10%
Jennifer Gudeman Vice President, Medical and Clinical Affairs at Avadel Pharmaceuticals plc-
St Louis, Missouri, United States
-
Rising Star
Jenny L. Reid Marketing Executive | Pharmaceuticals & Emerging Biopharma | Results-Driven Strategic Leader | Innovative Problem-Solver | Patient-Centric Partner | CNS, Rare Disease, Gene Therapy-
Greater St. Louis
-
Top 5%
Overview
Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. At Avadel, our core values foster an atmosphere of innovation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with narcolepsy. Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.
-